Crixus BH3 Acquisition Shutting Down Next Month

Crixus BH3 Acquisition in an 8-K said intends to discontinue its pursuit of a business combination and will liquidate the trust. The Sept. 20 shareholders meeting is cancelled.

Subject to the approval by the board, the SPAC expects to redeem stock no more than 10 business days after Sept. 6, when shares will cease to trade on the Nasdaq Global Market.

Crixus BH3 raised $200 million in an October 2021 IPO to focus on businesses that manage, finance, operate, construct, control, own or support real estate. Redemptions erased 63% of the trust in January. Read more.

Total
0
Shares
Related Posts
Read More

Achari Ventures I Files Proxy on $176M Vaso Deal

Vaso is a diversified medical technology company with several specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for diagnostic imaging products; and design, manufacture and sale of proprietary medical devices.